Apparatus for the non-invasive measurement of tissue function and metabolism by determination of steady-state fluorescence anisotropy

• US 8,309,346 B2
• Filed: 10/10/2007
• Issued: 11/13/2012
• Est. Priority Date: 04/13/2006
• Status: Active Grant

• Current Assignee: Cellview Imaging Inc.
• Original Assignee: Ralph Zuckerman
• Inventors: Zuckerman, Ralph
• Primary Examiner(s): Weber, Jon P
• Assistant Examiner(s): SINGH, SATYENDRA K
• Application Number:
  US11/870,355
• Publication Number:
  US 20080254531A1
• Time in Patent Office: 1,861 Days
• Field of Search: None
• US Class Current: 435/288.7
• CPC Class Codes: A61B 5/0071 by measuring fluorescence emission
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/14555 specially adapted for the eye fundus
• CPC Class Codes: A61B 5/14556 by fluorescence A61B5/14555 takes precedence
• CPC Class Codes: A61B 5/4842 Monitoring progression or stage of a disease
• CPC Class Codes: A61B 5/7246 using correlation, e.g. template matching or determination of similarity
• CPC Class Codes: A61B 5/7278 Artificial waveform generation or derivation, e.g. synthesising signals from measured signals A61B5/327 takes precedence
• CPC Class Codes: G01N 2021/6484 Optical fibres
• CPC Class Codes: G01N 21/6445 Measuring fluorescence polarisation
• CPC Class Codes: G01N 21/645 Specially adapted constructive features of fluorimeters
• CPC Class Codes: G01N 2201/0683 Brewster plate; polarisation controlling elements
• CPC Class Codes: G01N 2201/12 Circuits of general importance; Signal processing

Abstract

A non-invasive measurement of biological tissue reveals information about the function of that tissue. Polarized light is directed onto the tissue, stimulating the emission of fluorescence, due to one or more endogenous fluorophors in the tissue. Fluorescence anisotropy is then calculated. Such measurements of fluorescence anisotropy are then used to assess the functional status of the tissue, and to identify the existence and severity of disease states. Such assessment can be made by comparing a fluorescence anisotropy profile with a known profile of a control.

Claims

1. An apparatus for non-destructively evaluating the functional capacity of a living human tissue in situ in an intact living human being, comprising:

a component configured to stimulate a resting tissue to change its metabolism and become a stimulated tissue using a light stimulus;

a light source configured to irradiate the resting and stimulated tissue with continuous linearly polarized excitation light sufficient to cause endogenous lipoamide dehydrogenase (LipDH) to fluoresce;

a module configured to resolve the fluorescence of LipDH in the resting tissue into a first set of vector components and the fluorescence of LipDH in the stimulated tissue into a second set of vector components, wherein the first and second sets of vector components are parallel and perpendicular to a plane of polarization of the excitation light; and

a computing device configured to;

determine a resting fluorescence anisotropy of the resting tissue from the first set of vector components and a stimulated fluorescence anisotropy of the stimulated tissue from the second set of vector components;

construct a resting fluorescence anisotropy map based on the resting fluorescence anisotropy and a stimulated fluorescence anisotropy map based on the stimulated fluorescence anisotropy;

determine a functional capacity of the tissue by subtracting point by point or pixel by pixel the resting fluorescence anisotropy map from the stimulated fluorescence anisotropy map over the entire maps or within areas of interest; and

compare the functional capacity of the tissue to a database of normal metabolic levels obtained from a control tissue similarly evaluated to identify dysfunctional areas in the tissue.

2. The apparatus of claim 1, wherein the resting fluorescence anisotropy comprises steady-state fluorescence anisotropy of the resting tissue and the stimulated fluorescence anisotropy comprises steady-state fluorescence anisotropy of the stimulated tissue.

3. The apparatus of claim 1, wherein the tissue comprises ocular tissue.

4. The apparatus of claim 2, wherein the light stimulus comprises flickering light.

5. The apparatus of claim 1, wherein the tissue is selected from the group consisting of skin tissue, cervix tissue, abdominal tissue, esophagus tissue, stomach tissue, gut tissue, lung tissue, and ocular tissue.

6. The apparatus of claim 1, wherein the computing device is further configured to identify, based at least in part on the functional capacity of the tissue, a presence and severity of a disease.

7. The apparatus of claim 6, wherein the disease is selected from the group consisting of neurodegenerative disease and mitochondrial disease.

8. The apparatus of claim 6, wherein the disease comprises cancer.

9. The apparatus of claim 6, wherein the disease is selected from the group consisting of ocular posterior pathologies including diabetic retinopathy, age-related macular degeneration and primary open angle glaucoma, and other optic neuropathies.

10. The apparatus of claim 6, wherein the computing device is further configured to determine, based at least in part on the functional capacity, an efficacy of a treatment intervention.

11. The apparatus of claim 1, wherein the component used to stimulate the tissue is configured to stimulate using steady-state light with wavelengths of 400 to 700 nm.

12. The apparatus of claim 1, wherein the component used to stimulate the tissue is configured to use spatial gratings of light either stationary or moving to convert the tissue in the resting state to the stimulated state.

13. The apparatus of claim 1, wherein the computing device is further configured to:

determine the resting fluorescence anisotropy within a latency period of a metabolic response of the tissue to a saturating light; and

determine the stimulated fluorescence anisotropy outside the latency period of the metabolic response of the tissue to the saturating light.

14. The apparatus of claim 1, wherein the computing device is further configured to construct the resting fluorescence anisotropy map and the stimulated fluorescence anisotropy map at a plurality of depths within the tissue.

15. The apparatus of claim 1, wherein the computing device is further configured to construct three-dimensional volume maps for the tissue and the control tissue.

16. The apparatus of claim 15, wherein the computing device is further configured to determine the functional capacity of the tissue by subtracting point by point or pixel by pixel a resting three-dimensional fluorescence anisotropy volume map from a stimulated three-dimensional fluorescence anisotropy volume map over the entire maps or within areas of interest.

17. The apparatus of claim 16, wherein the computing device is further configured to identify dysfunctional areas in the tissue in a three-dimensional space.

18. The apparatus of claim 1, wherein the component used to stimulate the tissue is configured to change a steady-state fluorescence anisotropy of the tissue and a steady-state fluorescence anisotropy of the control tissue due to changes in the rotational correlation time (φ

) of any segment of LipDH free to rotate by a magnitude that exceeds the stimulus induced changes in the fluorescence lifetimes (τ

) according to the following equation;